Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul;48(7):2477-82.
doi: 10.1128/AAC.48.7.2477-2482.2004.

Patterns of amphotericin B killing kinetics against seven Candida species

Affiliations

Patterns of amphotericin B killing kinetics against seven Candida species

Emilia Cantón et al. Antimicrob Agents Chemother. 2004 Jul.

Abstract

In a previous study tolerance to amphotericin B (AMB) was found among Candida parapsilosis and C. dubliniensis strains by seeding the whole volumes of wells used for MIC determinations, and minimum fungicidal concentrations (MFC) for non-C. albicans Candida strains were demonstrated to be above the levels safely achievable in serum. As an extension of that study, we performed time-kill assays with 26 blood culture isolates (6 C. albicans, 5 C. parapsilosis, 5 C. krusei, 4 C. glabrata, 3 C. lusitaniae, and 3 C. tropicalis isolates), 3 oropharyngeal C. dubliniensis isolates, 3 AMB-susceptible isolates (ATCC 90028, ATCC 22019, ATCC 6254), and 6 AMB-resistant isolates (ATCC 200955, ATCC 200956, ATCC 200950, ATCC 200951, ATCC 200952, ATCC 200953) using RPMI 1640 medium and 0.12 to 32 microg of AMB per ml and determined the numbers of CFU per milliliter at 0, 2, 4, 8, 12, 24, and 48 h. MFCs and time-kill patterns were species specific (MFCs, < or =1 microg/ml for all C. dubliniensis and C. albicans isolates except AMB-resistant strain ATCC 200955; MFCs, 2 to >16 microg/ml for the other isolates). The times required to reach the fungicidal endpoint (99.9% killing) at four times the MIC were 2 h for C. albicans and C. dubliniensis, 16 h for C. glabrata, 24 h for C. parapsilosis and C. lusitaniae, and > or =40 h for C. tropicalis and C. krusei. The killing rate increased as the AMB concentration was increased up to 2 microg/ml. The highest killing rates were achieved for C. albicans, C. dubliniensis, and C. lusitaniae, while viable C. tropicalis, C. krusei, and C. parapsilosis cells were present after 48 h (MICs, < or =2 microg/ml) when AMB was used at 2 microg/ml. Time-kill curves and MFCs can detect viable cells after 48 h when AMB is used at > or =2 microg/ml. The failure of AMB treatment could be due to its poor killing activity against some species at the concentrations reached in patients' serum.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Representative time-kill plots for Candida species following exposure to amphotericin B. Average datum points and standard deviations are provided for six C. albicans, three C. dubliniensis, five C. parapsilosis, five C. krusei, four C. glabrata, three C. tropicalis, and three C. lusitaniae strains at the following concentrations: no drug (control; ♦), 0.03 μg/ml (⋄), 0.12 μg/ml (▴), 0.25 μg/ml (□), 0.5 μg/ml (▪), 1 μg/ml (×), 2 μg/ml (dashed line), 8 μg/ml (•), and 32 μg/ml (+). As the curves for some concentrations overlap, see Fig. 2 for a better visualization of the effects of the different concentrations.
FIG. 2.
FIG. 2.
(A) Relationship of amphotericin B concentrations and K values calculated from the regression line of survival times for C. dubliniensis (CD), C. albicans (CA), C. lusitaniae (CL), C. parapsilosis (CP), C. glabrata (CG), C. krusei (CK), and C. tropicalis (CT). (B) Amplification of the area marked with dotted lines in panel A.
FIG. 3.
FIG. 3.
Representative plots of mean ± standard deviation time-kill curves for several Candida species with 2 μg of amphotericin B per ml: C. dubliniensis (CD; □), C. albicans (CA; ⋄), C. lusitaniae (CL; +), C. parapsilosis (CP; ▵), C. glabrata (CG; ×), C. krusei (CK; ▪), and C. tropicalis (CT; •).

References

    1. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (Ambisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833. - PMC - PubMed
    1. Burguess, S. D., R. W. Hasting, K. K. Summers, T. C. Harding, and M. G. Rinaldi. 2000. Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn. Microbiol. Infect. Dis. 36:13-18. - PubMed
    1. Cantón, E., and J. Pemán. 1999. Curvas de letalidad en antifúngicos. Rev. Iberoam. Micol. 16:82-85. - PubMed
    1. Cantón, E., J. Pemán, A. Viudes, G. Quindós, M. Gobernado, and A. Espinel-Ingroff. 2003. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45:203-206. - PubMed
    1. Diekeman, D. J., M. A. Pfaller, R. N. Jones, and SENTRY Participants Group. 2002. Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. Int. J. Antimicrob. Agents 20:412-418. - PubMed